Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 20/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18694378 | 1.00 | CFTR (0.61) | CFTRCYP2C9HRH1TMEM97SIGMAR1 | |
| SCHEMBL18693595 | 0.94 | CFTR (0.65) | CFTRCYP2C9HRH1TMEM97SIGMAR1 | |
| SCHEMBL18694632 | 0.91 | CFTR (0.57) | CFTRCYP2C9HRH1TMEM97SIGMAR1 | |
| SCHEMBL18694042 | 0.91 | CFTR (0.57) | CFTRCYP2C9HRH1TMEM97SIGMAR1 | |
| SCHEMBL18693930 | 0.91 | CFTR (0.57) | CFTRCYP2C9HRH1TMEM97SIGMAR1 | |
| SCHEMBL18694211 | 0.91 | CFTR (0.57) | CFTRCYP2C9HRH1TMEM97SIGMAR1 | |
| SCHEMBL18694111 | 0.91 | CFTR (0.57) | CFTRCYP2C9HRH1TMEM97SIGMAR1 | |
| SCHEMBL18694775 | 0.89 | CFTR (0.55) | CFTRCYP2C9HRH1TMEM97SIGMAR1 | |
| SCHEMBL18694329 | 0.89 | CFTR (0.55) | CFTRCYP2C9HRH1TMEM97SIGMAR1 | |
| SCHEMBL20077408 | 0.89 | CFTR (0.59) | CFTRCYP2C9HRH1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | claimed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | claimed |
| US-10130622-B2 | Compounds for treatment of cystic fibrosis | ABBVIE S.Á.R.L. (LU) | 2018-11-20 | — | — | US | disclosed |
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | disclosed |
| US-20170100386-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | ABBVIE S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | CFTR, CHRM3, P2RY1 | CFTR 1/4885CYP2C9 656/4885HRH1 93/4885 |
| US-10130622-B2 | Compounds for treatment of cystic fibrosis | CFTR, CLCN2, SLC26A4 | CFTR 1/4885CYP2C9 4689/4885HRH1 1971/4885 |
| US-20170100386-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, CLCN2, SLC26A4 | CFTR 1/4885CYP2C9 4806/4885HRH1 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.